Pharma BD Deal Intelligence
A $1 billion royalty grab that collapsed under its own timing: Elan agreed to pay cash for 21% of Theravance's Breo and Anoro royalty stream, but its own shareholders voted the deal down in June 2013 amid Royalty Pharma's rival takeover bid for Elan itself.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The Theravance split into a royalty holding co and an R&D operating co was framed as a 'clean takeout' setup for GSK to ultimately consolidate the Breo/Anoro…
Royalty Pharma publicly attacked the Elan-Theravance deal as overpriced and a defensive maneuver, urging Elan shareholders to reject the transaction.
Elan shareholders voted down the Theravance royalty participation transaction in June 2013 amid Royalty Pharma's competing bid for Elan, terminating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Elan agreed $1B cash for 21% of Theravance's royalties on its GSK-partnered respiratory programs (Breo, Anoro, vilanterol, MABA); deal ultimately voted down by Elan shareholders amid Royalty Pharma takeover battle.
$8.0B Advair global sales ~$8B in 2013 (anchor for ICS/LABA category)
COPD is a progressive obstructive lung disease, primarily smoking-related, marked by emphysema and chronic bronchitis. Asthma is a chronic inflammatory airway disease causing reversible bronchoconstriction. Both demand maintenance inhaled therapies, with combination ICS/LABA, LAMA/LABA, and triple therapies driving the multi-billion-dollar respiratory category.
The Theravance/GSK respiratory portfolio targeted Advair (fluticasone/salmeterol) — a roughly $8B annual franchise facing patent erosion. Breo Ellipta (fluticasone furoate/vilanterol) was FDA-approved May 10, 2013 for COPD as the first once-daily ICS/LABA, intended as Advair's successor. Anoro Ellipta (umeclidinium/vilanterol) followed as a once-daily LAMA/LABA for COPD competing with Boehringer's Spiriva (tiotropium) and Novartis/GSK Ultibro/Anoro-class agents. Vilanterol monotherapy and the MABA bifunctional bronchodilator GSK961081 ('081) sat in earlier development as next-generation anchors. Elan's $1B purchase of 21% of Theravance's GSK royalty stream — including 15% of Breo's first $3B sales and a slice of Anoro royalties — was a financial bet on the GSK-led launches succeeding into the Advair gap. The deal was ultimately rejected by Elan shareholders amid Royalty Pharma's hostile bid, leaving Theravance to subsequently split into Innoviva (royalty-co holding the GSK respiratory streams) and an operating R&D entity. Source: https://www.cnbc.com/2013/05/13/elan-strikes-1-billion-royalty-deal-with-theravance.html
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Elan Corporation plc / Theravance Inc. (royalty interest) (this deal) | 2013 | $1.0B | — |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Madison Dearborn Partners / Ikaria, Inc. | 2013 | $1.6B | 85 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 2025 | $12.0B | 65 |
← Browse all deals · How we score deals
More: 2013 deals · Respiratory deals